Objective To explore the curative effects of bevacizumab integrated with temozolomide in the treatment of glioblastoma. Methods Fifty-four patients with glioblastoma admitted in our oncology department between May 2011 and July 2012 were randomly divided into two groups, 27 cases in each group. The control group was treated with temozolomide while the treatment group was treated with bevacizumab integrated with temozolomide. The therapeutic effect and adverse reactions were observed and compared between two groups after treatment. Results After 6 months’treatment, the RR was 37% in the treatment group but 26% in the control group, which was significantly higher in the treatment group (P=0.047); the DCR was 77.8% in the treatment group but 63% in the control group, which was significantly higher in the treatment group (P=0.01). After 12 months’treatment, the RR was 30.8% and 16.7% respectively in the treatment group and control group, also sig-nificantly higher in the treatment group(P=0.01); the DCR in the treatment group and control group were 65.4% and 37.5%respectively, also significantly higher in the treatment group (P<0.0001). However, there was no statistical difference in the side effects between the two groups (P>0.05). Conclusion The bevacizumab integrated with temozolomide in the treatment of glioblastoma had better curative effect than temozolomide alone. It was worthy of being popularized.%目的观察贝伐单抗联合替莫唑胺治疗胶质母细胞瘤的临床疗效。方法选择2011年5月至2012年7月在我院肿瘤科住院治疗的54例胶质母细胞瘤患者并将其随机分成对照组和治疗组，每组27例患者。对照组给予替莫唑胺治疗，治疗组给予贝伐单抗联合替莫唑胺治疗。治疗后，评价和比较两组患者的临床疗效及不良反应的发生情况。结果治疗6个月后，治疗组和对照组的疾病有效率（RR）分别为37％和26％，治疗组显著高于对照组（P=0.047）；治疗组和对照组的疾病控制率（DCR）分别为77.8％和63％，治疗组显著高于对照组（P=0.01）；治疗12个月后，治疗组和对照组的 RR 分别为30.8％和16.7％，治疗组显著高于对照组（P=0.01）；治疗组和对照组的 DCR 分别为65.4％和37.5％，治疗组显著高于对照组（P<0.0001）；两组的不良反应的发生情况相互比较，差异无统计学意义（P>0.05）。结论贝伐单抗联合替莫唑胺治疗胶质母细胞瘤临床疗效较单用替莫唑胺更好，值得临床推广。
展开▼
